Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07804979 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Comparison of Efficacy of Minocyclin and Celecoxib as Adjunctive Treatment in Treatment Resistant Cases of Major Depressive Disorder

StatusCompleted
PhaseNot applicable
Started2022-05-12
View on ClinicalTrials.gov ↗
This randomized controlled study was conducted to compare the effectiveness of minocycline and celecoxib as add-on treatments in patients with treatment-resistant major depressive disorder. Treatment-resistant depression was defined as depression that had not adequately improved despite appropriate previous antidepressant treatment. A total of 78 patients aged 18-65 years were enrolled from the Psychiatry Department of Lahore General Hospital, Lahore, and were randomly assigned to two treatment groups. One group received minocycline 100 mg twice daily with fluoxetine 20-40 mg, while the other group received celecoxib 200 mg twice daily with fluoxetine 20-40 mg. Treatment was continued for 12 weeks. Depressive symptoms were assessed using the Hamilton Depression Rating Scale (HAM-D) at baseline and during follow-up. The main outcome was the change in HAM-D score from baseline to the end of treatment. Treatment response was defined as a reduction of at least 50% in the HAM-D score, while remission was defined as a final HAM-D score of 7 or lower. The study was designed to test whether adding minocycline or celecoxib to fluoxetine would reduce depressive symptoms in treatment-resistant major depressive disorder and whether the degree of improvement differed between the two adjunctive treatments.
Trial Details
NCT Number NCT07804979
Lead Sponsor Lahore General Hospital
Conditions Major Depressive Disorder (MDD), Treatment-resistant Depression (TRD)
Enrollment 78 participants
Start Date 2022-05-12
Primary Completion 2023-06-17 (estimated)
Study Completion 2023-09-15 (estimated)
Updated on ClinicalTrials.gov 2026-09-04